


**PRODUCT: VX-11e**

**ALTERNATE NAMES:** VX11e; VX 11e; 4-[2-(2-chloro-4-fluoroanilino)-5-methylpyrimidin-4-yl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide

**CATALOG#:** B1681-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>24</sub>H<sub>20</sub>Cl<sub>2</sub>FN<sub>5</sub>O<sub>2</sub>

**MOLECULAR WEIGHT:** 500.35

**CAS NUMBER:** 896720-20-0

**APPEARANCE:** Solid powder

**SOLUBILITY:** DMSO

**PURITY:** >98%

**STORAGE:** Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

**DESCRIPTION:** VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK (Extracellular Signal-Regulated Kinase); antitumor agent.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCES:**

1. Aronov, Alex M et al. Structure-Guided Design of Potent and Selective Pyrimidopyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. Journal of Medicinal Chemistry (2009), 52(20), 6362-6368.
2. Krepler C et al. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 2016 Apr 1;22(7):1592-602.

**RELATED PRODUCTS:**

- PD184352 (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD 98059 (Cat. No. 1666-5)
- EZSolution™ PD 98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB-203580 (Cat. No. 1786-1)
- U0126 (Cat. No. 1668-5)
- Sorafenib (Cat. No. 1594-25, 100)
- VX-702 (Cat. No. 1598-1, 5)

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**